1.Whole-process supervision of medical consumables based on codes of medical insurance medical consumbles
Fang-Li HE ; Hong XIN ; Jian-Xue ZHOU ; Peng-Fa WANG ; Jing CHEN ; Ni-Ni LYU ; Hai-Bing FAN ; Yan LIU
Chinese Medical Equipment Journal 2023;44(9):74-77
		                        		
		                        			
		                        			The medical insurance medical consumables were introuduced in terms of coding and standard implementation.A whole-process supervision method based on the codes of medical insurance medical consumbles was put forward to carry out catalog classification and selection,demand reporting and planned procurement,acceptance and storage management and use supervision,conditions monitoring and analysis and etc.The efficiency of various departments of clinical insitutitions was enhanced effectively for supervising clinical application of medical consumables,and the whole-process management of medical consumables was standardized.References were provided for the precision management of medical consumables.[Chinese Medical Equipment Journal,2023,44(9):74-77]
		                        		
		                        		
		                        		
		                        	
2.The rules of acupoint selection of acupuncture and moxibustion for aphasia based on data mining.
Lei XU ; Ling HE ; Hui LI ; Hai-Fa QIAO ; Qiang WANG ; Yuan WANG
Chinese Acupuncture & Moxibustion 2023;43(4):471-478
		                        		
		                        			OBJECTIVE:
		                        			To explore the rules of acupoint selection for aphasia treated with acupuncture and moxibustion using data mining technology.
		                        		
		                        			METHODS:
		                        			From January 1, 2000 to April 1, 2022, the articles for clinical researches of acupuncture and moxibustion for aphasia published in CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase were searched. Using Microsoft Excel 2021, the database was set up to analyze the use frequency of acupoint, meridian tropism, acupoint distribution and the use of specific points. SPSS26.0 was adopted for factor analysis, SPSS Modeler 18.0 was for association rule analysis of prescriptions, and Gephi 0.9.5 was to plot the co-occurrence network diagrams of acupoints and meridians.
		                        		
		                        			RESULTS:
		                        			A total of 140 articles were collated, including 146 acupuncture and moxibustion prescriptions and 189 acupoints. The total use frequency of these acupoints was 1 211. Lianquan (CV 23), Jinjin (EX-HN 12), Yuye (EX-HN 13), Baihui (GV 20) and Yamen (GV 15) were the top 5 acupoints of the high use frequency for aphasia treated with acupuncture and moxibustion. Among 189 acupoints collected, the extra points and empirical points were mostly selected. The top 3 involved meridians were the governor vessel, the gallbladder meridian of foot-shaoyang and the conception vessel. These acupoints were mostly distributed on the head, face and neck region. The use frequency of five-shu points was the highest among the specific points. The acupoint combinations of high frequency referred to Yuye (EX-HN 13)-Jinjin (EX-HN 12), Yuye (EX-HN 13)-Lianquan (CV 23)-Jinjin (EX-HN 12), and Fengchi (GB 20)-Yuye (EX-HN 13)-Jinjin (EX-HN 12). Factor analysis extracted 10 common factors for acupoint compatibility in treatment of aphasia with acupuncture and moxibustion.
		                        		
		                        			CONCLUSION
		                        			In clinical treatment of aphasia with acupuncture and moxibustion, the local acupoints are preferred. The core acupoints include Lianquan (CV 23), Jinjin (EX-HN 12), Yuye (EX-HN 13), Baihui (GV 20) and Yamen (GV 15). The acupoint prescription is modified flexibly according to syndrome differentiation to enhance the therapeutic effect.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Moxibustion
		                        			;
		                        		
		                        			Acupuncture Points
		                        			;
		                        		
		                        			Acupuncture Therapy
		                        			;
		                        		
		                        			Meridians
		                        			;
		                        		
		                        			Data Mining
		                        			;
		                        		
		                        			Aphasia/therapy*
		                        			
		                        		
		                        	
3.Long non-coding RNA LINC01133 regulates cementogenic differentiation of human periodontal ligament stem cells by modulating mitochondrial functions.
Dao Kun DENG ; Xuan LI ; Xiao Tao HE ; Hai Hua SUN ; Bei Min TIAN ; Fa Ming CHEN
Chinese Journal of Stomatology 2022;57(12):1209-1216
		                        		
		                        			
		                        			Objective: To investigate the effects of long non-coding RNA (lncRNA) LINC01133 on the cementogenic differentiation of human periodontal ligament stem cells (hPDLSC) and the underlying mechanism. Methods: A total of 12 teeth were harvested from 10 patients aged 17-30 years in the Department of Oral and Maxillofacial Surgery, School of Stomatology, The Fourth Military Medical University for impacted or orthodontic reasons from September 2021 to January 2022. The hPDLSCs were isolated from the teeth and transfected with small interfering RNA-LINC01133 (si-LINC01133) or small interfering RNA-negative control (si-NC). The si-LINC01133 was regarded as the experimental group, and the si-NC was regarded as the control one. The silencing efficiency of LINC01133 in the hPDLSCs was evaluated by real-time quantitative PCR (RT-qPCR). Western blotting was used to detect the protein expression levels of cementogenic differentiation-related factors including bone sialoprotein (BSP), cementum attachment protein (CAP), and cementum protein-1 (CEMP-1). Mitochondrial reactive oxygen species (mtROS) production was assessed using the MitoSox by flow cytometry. Mitochondrial membrane potential (MMP) was detected by JC-1 fluorescence staining. Mitochondrial respiratory chain complexes proteins including NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8 (NDUFB8), succinate dehydrogenase complex flavoprotein subunit A (SDHA), ubiquinol-cytochrome c reductase core protein 1 (UQCR1), cytochrome c oxidase subunit 4 isoform 1 (COXⅣ), and ATP synthase F1 subunit alpha (ATP5A) were evaluated by Western blotting. Results: The expression levels of LINC01133 could be suppressed by more than 60% with si-LINC01133 (control group: 1.000±0.000, experimental group: 0.385±0.128) (t=10.72, P<0.01). Suppression of LINC01133 in hPDLSCs decreased the levels of cementogenic differentiation-related proteins including BSP (control group: 1.000±0.000, experimental group: 0.664±0.179) (t=4.62, P<0.01) and CAP (control group: 1.000±0.000, experimental group: 0.736±0.229) (t=2.83, P<0.05). Suppression of LINC01133 in hPDLSCs increased the production of mtROS (control group: 1.000±0.000, experimental group: 1.458±0.185) (t=4.96, P<0.05) and the expression of NDUFB8 (control group: 1.000±0.000, experimental group: 1.683±0.397) (t=3.45, P<0.05), as well as decreased MMP levels (control group: 1.000±0.000, experimental group: 0.209±0.029) (t=53.99, P<0.01) and the expression of SDHA (control group: 1.000±0.000, experimental group: 0.428±0.228) (t=5.02, P<0.05). No significant changes in the UQCR1, COXⅣ, and ATP5A expression levels were found between the control group and exprimental group (P>0.05). Conclusions: LINC01133 regulates the cementogenic differentiation of hPDLSCs possibly via modulating the mitochondrial functions.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Periodontal Ligament
		                        			;
		                        		
		                        			RNA, Long Noncoding/metabolism*
		                        			;
		                        		
		                        			Cells, Cultured
		                        			;
		                        		
		                        			Stem Cells
		                        			;
		                        		
		                        			Cell Differentiation
		                        			;
		                        		
		                        			Integrin-Binding Sialoprotein/metabolism*
		                        			;
		                        		
		                        			Mitochondrial Proteins/metabolism*
		                        			;
		                        		
		                        			Mitochondria/genetics*
		                        			;
		                        		
		                        			RNA, Small Interfering/metabolism*
		                        			;
		                        		
		                        			Osteogenesis
		                        			
		                        		
		                        	
4. Based on PI3K/Akt signaling pathway to explore the effects of olanzapine on cognitive function and neuronal damage in schizophrenic rats
Hai-Long ZHONG ; Xun-Ying JIANG ; Zhu-Fa HE ; Zhong-Zhen MAO
Acta Anatomica Sinica 2022;53(6):719-726
		                        		
		                        			
		                        			 Objective To explore olanzapine effect on the cognitive function and neuronal damage of aged schizophrenic rats based on the PI3 K/Akt signaling pathway. Methods Ten-week-old SD rats were randomly divided into a blank control group(n=12) and a modeling intervention group(n=48). The modeling group were injected with didroxapine maleate [MK-801,0.2 mg/(kg·d)] for 14 days. And the model was evaluated by general behavioral studies to determine the success of model building. The model rats were randomly divided into model group and low, medium, and high dose olanzapine groups [10, 20, 40 mg/(kg·d)], each with 12 rats. The control group and model group were given distilled water; the low, medium, and high dose olanzapine groups were given olanzapine for 21 days. The stereotyped lines were scored by the standard of Sams Dodd and Hoffman, the cognitive evaluation of the rats was performed by the Morris water maze, and the levels of interleukin-6(IL-6) and tumor necrosis factor-α(TNF-α) in the serum were determined by ELISA. The activities of dihydrokaempferol(Ach) and acetyl cholinesterase(AchE)in brain tissue were detected by acetylcholinesterase activity assay kit. Rat brain tissue PI3 K, Akt, mammalian target of rapamycin(mTOR) mRNA expression levels were detected by Real-time PCR. Results Compared with the model group, the stereotyped behavior and ataxia scores, escape latency, number of crossing platforms, serum levels of IL-6, TNF-α, AchE, phosphorylated PI3 K(p-PI3 K), phosphorylated Akt(p-Akt) protein expression decreased(P<0.05 or P<0.01), while brain tissue Ach, PI3 K, mTOR and phosphorylated mTOR(p-mTOR) protein content increased(P<0.05 or P<0.01) in the low, medium and high dose olanzapine groups. The content of Akt was increased in the low-dose group. Compared with the model group, Akt and mTOR mRNA in the brain tissue of rats in the low, medium, and high-dose alanzapine groups expression levels were down-regulated(P<0.05 or P<0.01). PI3 K mRNA in the brain tissue of rats in the low, medium, and high-dose alanzapine groups expression levels were down-regulated(P<0.05 or P<0.01). Conclusion Olanzapine can reduce stereotyped behavior and ataxia scores, escape latency, number of crossing platforms, IL-6, TNF-α, AchE and increase Ach content and regulate the PI3 K/Akt signaling pathway to relieve the schizophrenia. 
		                        		
		                        		
		                        		
		                        	
5.A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data.
Xue Wei DING ; Zhi Chao ZHENG ; Qun ZHAO ; Gang ZHAI ; Han LIANG ; Xin WU ; Zheng Gang ZHU ; Hai Jiang WANG ; Qing Si HE ; Xian Li HE ; Yi An DU ; Lu Chuan CHEN ; Ya Wei HUA ; Chang Ming HUANG ; Ying Wei XUE ; Ye ZHOU ; Yan Bing ZHOU ; Dan WU ; Xue Dong FANG ; You Guo DAI ; Hong Wei ZHANG ; Jia Qing CAO ; Le Ping LI ; Jie CHAI ; Kai Xiong TAO ; Guo Li LI ; Zhi Gang JIE ; Jie GE ; Zhong Fa XU ; Wen Bin ZHANG ; Qi Yun LI ; Ping ZHAO ; Zhi Qiang MA ; Zhi Long YAN ; Guo Liang ZHENG ; Yang YAN ; Xiao Long TANG ; Xiang ZHOU
Chinese Journal of Gastrointestinal Surgery 2021;24(5):403-412
		                        		
		                        			
		                        			Objective: To explore the effect of perioperative chemotherapy on the prognosis of gastric cancer patients under real-world condition. Methods: A retrospective cohort study was carried out. Real world data of gastric cancer patients receiving perioperative chemotherapy and surgery + adjuvant chemotherapy in 33 domestic hospitals from January 1, 2014 to January 31, 2016 were collected. Inclusion criteria: (1) gastric adenocarcinoma was confirmed by histopathology, and clinical stage was cT2-4aN0-3M0 (AJCC 8th edition); (2) D2 radical gastric cancer surgery was performed; (3) at least one cycle of neoadjuvant chemotherapy (NAC) was completed; (4) at least 4 cycles of adjuvant chemotherapy (AC) [SOX (S-1+oxaliplatin) or CapeOX (capecitabine + oxaliplatin)] were completed. Exclusion criteria: (1) complicated with other malignant tumors; (2) radiotherapy received; (3) patients with incomplete data. The enrolled patients who received neoadjuvant chemotherapy and adjuvant chemotherapy were included in the perioperative chemotherapy group, and those who received only postoperative adjuvant chemotherapy were included in the surgery + adjuvant chemotherapy group. Propensity score matching (PSM) method was used to control selection bias. The primary outcome were overall survival (OS) and progression-free survival (PFS) after PSM. OS was defined as the time from the first neoadjuvant chemotherapy (operation + adjuvant chemotherapy group: from the date of operation) to the last effective follow-up or death. PFS was defined as the time from the first neoadjuvant chemotherapy (operation + adjuvant chemotherapy group: from the date of operation) to the first imaging diagnosis of tumor progression or death. The Kaplan-Meier method was used to estimate the survival rate, and the Cox proportional hazards model was used to evaluate the independent effect of perioperative chemo therapy on OS and PFS. Results: 2 045 cases were included, including 1 293 cases in the surgery+adjuvant chemotherapy group and 752 cases in the perioperative chemotherapy group. After PSM, 492 pairs were included in the analysis. There were no statistically significant differences in gender, age, body mass index, tumor stage before treatment, and tumor location between the two groups (all P>0.05). Compared with the surgery + adjuvant chemotherapy group, patients in the perioperative chemotherapy group had higher proportion of total gastrectomy (χ(2)=40.526, P<0.001), smaller maximum tumor diameter (t=3.969, P<0.001), less number of metastatic lymph nodes (t=1.343, P<0.001), lower ratio of vessel invasion (χ(2)=11.897, P=0.001) and nerve invasion (χ(2)=12.338, P<0.001). In the perioperative chemotherapy group and surgery + adjuvant chemotherapy group, 24 cases (4.9%) and 17 cases (3.4%) developed postoperative complications, respectively, and no significant difference was found between two groups (χ(2)=0.815, P=0.367). The median OS of the perioperative chemotherapy group was longer than that of the surgery + adjuvant chemotherapy group (65 months vs. 45 months, HR: 0.74, 95% CI: 0.62-0.89, P=0.001); the median PFS of the perioperative chemotherapy group was also longer than that of the surgery+adjuvant chemotherapy group (56 months vs. 36 months, HR=0.72, 95% CI:0.61-0.85, P<0.001). The forest plot results of subgroup analysis showed that both men and women could benefit from perioperative chemotherapy (all P<0.05); patients over 45 years of age (P<0.05) and with normal body mass (P<0.01) could benefit significantly; patients with cTNM stage II and III presented a trend of benefit or could benefit significantly (P<0.05); patients with signet ring cell carcinoma benefited little (P>0.05); tumors in the gastric body and gastric antrum benefited more significantly (P<0.05). Conclusion: Perioperative chemotherapy can improve the prognosis of gastric cancer patients.
		                        		
		                        		
		                        		
		                        			Chemotherapy, Adjuvant
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Gastrectomy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Neoadjuvant Therapy
		                        			;
		                        		
		                        			Neoplasm Staging
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Stomach Neoplasms/surgery*
		                        			
		                        		
		                        	
7.Clinical trial of tiotropium bromide powder inhalation combined with salmeterol xinafoate and fluticasone propionate powder inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease complicated with respiratory failure
Fa-Hui WANG ; Hui-Fang SHI ; Shi-Ning LIN ; Jian-Guang XU ; Hai-Wu HE ; Qiu-Ting WANG
The Chinese Journal of Clinical Pharmacology 2018;34(5):497-500
		                        		
		                        			
		                        			Objective To observe the clinical efficacy and safety of tiotropium bromide powder inhalation combined with salmeterol xinafoate and fluticasone propionate powder inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (COPD) complicated with respiratory failure.Methods Seventy-six patients with acute exacerbation of COPD complicated with respiratory failure were randomly divided into control group and treatment group with 38 cases per group.Control group received routine treatment and ventilator-assisted ventilation treatment.Treatment group received salmeterol xinafoate and fluticasone propionate powder inhalation 1 suction,bid,inhalation treatment +tiotropium bromide powder inhalation 18 μg,qd,inhalation treatment,on the basis of control group.Two groups were treated for 2 weeks.The clinical efficacy,arterial blood gas indexes,procalcitonin,immune functions and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates of treatment and control groups were 92.11% (35 cases/38 cases) and 73.68% (28 cases/38 cases) with significant difference (P <0.05).After treatment,the main indexes in treatment and control groups were compared:arterial partial pressure of oxygen were (86.35 ±7.04) and (77.49 ±6.85)mmHg,oxygenation index were (310.89 ±29.87) and (281.34 ±27.53)mmHg,procalcitonin were (1.42 ± 0.54) and (1.93 ± 0.61)ng · mL-1,tumor necrosis factor-α were (275.49 ±48.62) and (310.05 ±54.73)ng · L-1,interleukin-8 were (312.62 ±75.64) and (389.75 ±78.76)pg · mL-1,high sensitive C-reactive protein were (4.73 ±2.45) and (8.34 ±2.53)mg · L-1,the differences were statistically significant (all P < 0.05).There were no adverse drug reactions in the two groups during the treatment.Conclusion Tiotropium bromide powder inhalation combined with salmeterol xinafoate and fluticasone propionate powder inhalation has a definitive clinical efficacy and safety in the treatment of acute exacerbation of COPD complicated with respiratory failure,which can significantly reduce the levels of procalcitonin,improve the blood gas indexes and immune function.
		                        		
		                        		
		                        		
		                        	
8.Analysis of Reference Intervals of 18 Routine Biochemistry in 56 Mutual Recognition Laboratories in Beijing-Tianjing-Hebei Region
ting Ting LI ; jian Hai ZHAO ; Wei WANG ; lin Fa HE ; Kun ZHONG ; Shuai YUAN ; guo Zhi WANG
Journal of Modern Laboratory Medicine 2017;32(6):154-159
		                        		
		                        			
		                        			Objective To evaluate reference intervals consistency of 18 routine biochemistry among mutual recognition labora-tories by analyzing the information of reference intervals of these laboratories in Beijing-Tianjing-Hebei region.Methods Laboratories submitted the data of reference intervals via interval quality assessment(EQA)software which was based on WEB,then the background of the software save the data as Microsoft Excel 2007 document.Finally,the mutual recognition routine biochemical projects,including Kalium(K),Sodium(Na),Chlorinum(Cl),Calcium(Ca),Phosphorus(P),Total protein(TP),Albumin(ALB),Total cholesterol(TC),Triglyceride(TG),Creatinine(CRE),Urea(URE),Uric acid (UA),Glucose(GLU),Alanine amino transaminase(ALT),Aspartate aminotransferase(AST),γ-glutamyltranspeptidase (GGT),Lactate dehydrogenase(LDH)and Creatine kinase(CK)of 56 mutual recognition laboratories were chosen,and perform analysis on upper and lower limits of reference intervals and their sources.Results The sources of reference inter-vals differ among different laboratories.As for projects owning hygiene professional standards(including K,Na,Cl,Ca,P, TP,ALB,CRE,URE,ALT,AST,GGT,LDH,CK),the primary sources were hygiene professional standards(23.1%~48.1%),manufacturer instructions of reagents/instrument(17.3%~41.8%)and National Clinical Laboratory Procedures (18.9% ~37.0%),as for projects which didn't have professional standards(including TC,TG,UA and GLU),the main sources were manufacturer instructions of reagents/instrument(>41.1%)and National Clinical Laboratory Procedures(>45.3%).Moreover,more than half of laboratories(50.9%~58.9%)had verified the reference intervals.There were little difference among laboratories in the upper and lower limits of Cl,Ca,P,K and GLU,but bigger difference for other projects. Conclusion The upper and lower limits of reference intervals werenot consistent among laboratories.In order to ensure the comparability of the test results in beijing-tianjin-hebei region,laboratories should use reference intervals based on the popu-lation of beijing-tianjin-hebei region or China.
		                        		
		                        		
		                        		
		                        	
9.Investigation on reasons of unacceptable external quality assessment results for blood gas and acid-base analysis in China
ting Ting LI ; jian Hai ZHAO ; bao Chuan ZHANG ; Wei WANG ; lin Fa HE ; Kun ZHONG ; Shuai YUAN ; guo Zhi WANG
Chinese Journal of Clinical Laboratory Science 2017;35(9):711-715
		                        		
		                        			
		                        			Objective To investigate the reasons of unacceptable results and corrective measures adopted in external quality assessment (EQA)for blood gas and acid-base analysis.Methods The reasons of unacceptable results and corrective measures for three EQA testing events of blood gas and acid-base analysis in 2016 were reported through EQA system based on web which was developed by National Central for Clinical Laboratories.The responses were divided into seven major groups,including EQA samples,errors in reporting results,methodology,equipments,techniques,EQA evaluations and unexplainable results after survey.Results The disqualified rates of EQA survey on blood gas and acid-base analysis were ranged from 0.5% to 13.1% and reporting rates of disqualification causes were ranged from 45.8% to 69.0% (except for the groups less than 20 laboratories).In the reasons for unacceptable results technological defects (35.9% to 37.0%)were mainly associated with inappropriate specimen handling and/or storing,reagents and calibration problems.The defects of equipments (24.4% to 27.9%) included mainly the malfunction and failure to adhere to scheduled instrument maintenance procedures.The errors in reporting results (12.2% to 19.7%) were mostly transcription errors and reporting wrong codes.The unexplainable results after survey account for 8.7% to 9.6%.The methodological defects (8.1% to 11.8%) were largely attributed to inadequate training and quality control method.The defects of EQA evaluations (0.8% to 3.3%)were all due to inappropriate grouping.The categorizations of the problems in the three EQA testing events were similar.The most corrective measures were appropriate,in which re-education and training for staff and improvement in instruments,reagents,internal quality control,calibration and process of reporting results were included.Conclusion The analysis and classification for reasons of unacceptable EQA results should be helpful for laboratories in identifying opportunities for improvement and adopting corrective measures in time.
		                        		
		                        		
		                        		
		                        	
10.Interpretation of External Quality Assessment Results in Clinical Laboratories and Suggested Approach on Investigating Unacceptable Results
ting Ting LI ; Wei WANG ; jian Hai ZHAO ; lin Fa HE ; Kun ZHONG ; Shuai YUAN ; guo Zhi WANG
Journal of Modern Laboratory Medicine 2017;32(5):152-156
		                        		
		                        			
		                        			Important objectives of external quality assessment (EQA) is to detect analytical errors and urge laboratories to take corresponding corrective actions.The paper described knowledge required to interpret EQA results and present a structured approach on how to handle unacceptable EQA results.The interpretation of EQA results depends on five key points:the control material,the target value,the number of replicates,the acceptance limits and between lot variations in reagents.When there are unacceptable EQA results,these factors may be the sources of errors.The ideal EQA sample has two important properties:having no matrix effects;having a target value established with a reference method.If either of these two criteria is not entirely fulfilled,results not related to the performance of the laboratory may arise.To help and guide the laboratories in handling an unacceptable EQA result,National Center for Clinical Laboratories has developed a preliminary investigation on the sources of errors and corrective actions for nonconforming EQA results in fifteen EQA schemes.Then a flow chart with additional comments was developed based on the investigation and the document of QMS24 to help laboratories improve quality by use of EQA results.
		                        		
		                        		
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail